Combination therapy with renin-angiotensin system blockers: Will amlodipine replace hydrochlorothiazide?

Current Hypertension Reports

Volumn 9, Issue 4, 2007, Pages 284-290

  Tejada, Thor ^b   Fornoni, Alessia ^b   Lenz, Oliver ^b   Materson, Barry J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; GALLOPAMIL; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; PHENYLALKYLAMINE; POTASSIUM; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ANGINA PECTORIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; PERIPHERAL EDEMA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 34548543777     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0052-0     Document Type: Review

References (53)

1. Scholz H: Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 1997, 10(Suppl 3):869-872.
2. Materson BJ: Calcium channel blockers: is it time to split the lump? Am J Hypertens 1995, 8:325-329.
3. Epstein M: Calcium channel blockers and hypertension: evolving perspectives - 1996. Cardiovasc Drugs Ther 1997, 10:883-891.
4. Triggle DJ: Calcium-channel drugs: structure-function relationships and selectivity of action. J Cardiovasc Pharmacol 1991, 18:S1-S6.
5. Triggle DJ: 1,4-dihydropyridines as calcium channel ligands and privileged structures. Cell Mol Neurobiol 2003, 23:293-303.
6. Ruzicka M, Leenen FHH: Relevance of 24-h blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996, 9:86-94.
7. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on vaisartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
8. Valcarcel Y, Jimenez R, Hernandez V, et al.: Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres. Clin Drug Investig 2006, 26:125-133.
9. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
10. Kloner RA, Vetrovec GW, Materson BJ, Levenstein M: Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J Cardiol 1998, 81:163-169.
11. Hall WD, Reed JW, Flack JM, et al.: Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. Arch Intern Med 1998, 158:2029-2034.
12. Jollis JG, Simpson RJ Jr, Chowdhury MK, et al.: Calcium channel blockers and mortality in elderly patients with myocardial infarction. Arch Intern Med 1999, 159:2341-2348.
13. Wright JT Jr, Dunn JK, Cutler JA, et al.: Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005, 293:1595-1608.
14. Packer M, O'Connor CM, Ghali JK, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996, 335:1107-1114.
15. Mahe I, Chassany O, Grenard AS, et al.: Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction. Am J Cardiovasc Drugs 2003, 3:33-41.
16. Rahman M, Pressel S, Davis BR, et al.: Renal outcomes in high-risk hypertensive patients treated with an angintensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:936-946.
17. Barzilay JI, Davis BR, Cutler JA, et al.: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006, 166:2191-2201.
18. Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
19. Mancia G, Grassi G, Zanchetti A: New-onset diabetes and antihypertensive drugs. J Hypertens 2006, 24:3-10.
20. Aksnes TA, Reims HM, Kjeldsen SE, Mancia G: Antihypertensive treatment and new-onset diabetes mellitus. Curr Hypertens Rep 2005, 7:298-303.
21. Pahor M, Psaty BM, Alderman MH, et al.: Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000, 23:888-892.
22. Beltman FW, Heesen WF, Smit AJ, et al.: Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press 1998, 7:109-117.
23. Terpstra WF, May JF, Smit AJ, et al.: Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001, 19:303-309.
24. Mayer B: Translocation of endothelial nitric oxide synthase: another feat of amlodipine, a cardiovascular jack-of-all-trades. Cardiovasc Res 2006, 71:411-413.
25. Toba H, Nakagawa Y, Miki S, et al.: Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res 2005, 28:689-700.
26. Pitt B, Byington RP, Furberg CD, et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000, 102:1503-1510.
27. Nissen SE, Tuzcu EM, Libby P, et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004, 292:2217-2225.
28. Aboyans V, Lacroix P, Cassat C: Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure. JAMA 2005, 293:1187-1189.
29. Wang JG, Staessen JA, Yan L, et al.: Carotid intimamedia thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006, 37:1933-1940.
30. Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
31. Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
32. Malacco E, Vari N, Capuano V, et al.: A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003, 25:2765-2780.
33. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL: Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. J Hum Hypertens 1999, 13:477-483.
34. Ruilope LM, Malacco E, Khder Y, et al.: Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005, 27:578-587.
35. Ruschitzka FT, Luscher TF: Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Am Heart J 1997, 134:S31-S47.
36. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
37. Jamerson KA, Nwose O, Jean-Louis L, et al.: Initial angintensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004, 17:495-501.
38. Doyle J, Omvik P, Arikian S, et al.: A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Manag Care Interface 2001, 14:82-87.
39. Winer N, Folker A, Murphy JA, et al.: Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol 2005, 8:87-92.
40. Chrysant SG, Bakris GL: Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004, 17:590-596.
41. Volpe M, Junren Z, Maxwell T, et al.: Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther 2003, 25:1469-1489.
42. Tedesco MA, Natale F, Calabro R: Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich) 2006, 8:634-641.
43. Mahmud A, Feely J: Low-dose quadruple antihypertensive combination: more efficacious than individual agents - a preliminary report. Hypertension 2007, 49:272-275.
44. Zhang X, Xu X, Nasjletti A, Hintze TH: Andodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol 2000, 35:195-202.
45. Antonios TF, Cappuccio FP, Markandu ND, et al.: A diuretic is more effective than a beta-blocker in hypertensive patients not controlled on amlodipine and lisinopril. Hypertension 1996, 27:1325-1328.
46. Jamerson KA, Bakris GL, Wun CC, et al.: Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004, 17:793-801.
47. Davis BR, Piller LB, Cutler JA, et al.: Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006, 113:2201-2210.
48. Fogari R, Preti P, Zoppi A, et al.: Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002, 15:1042-1049.
49. Oparil S, Barr E, Elkins M, et al.: Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or in combination with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996, 18:608-625.
50. Stergiou GS, Makris T, Papavasiliou M, et al.: Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 2005, 23:883-889.
51. Kuriyama S, Tomonari H, Tokudome G, et al.: Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002, 25:849-855.
52. Homma K, Hayashi K, Kanda T, et al.: Beneficial action of candesartan cilexitil plus amlodipine or ACE inhihitors in chronic nondiabetic renal disease. J Hum Hypertens 2004, 18:879-884.
53. Uzunlulu M, Oguz A, Yorulmaz E: The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. Int Heart J 2006, 47:421-430.